|
|
|
|
|
|
The latest immunology news from News Medical
|
|
|
|
|
Sponsored by ACROBiosystems |
|
|
|
|
|
|
Supercharge Drug Discovery with Our Inhibitor Screening Kit
Harness the potential of ACRO's exclusive inhibitor screening kits for swift high-throughput identification of inhibiting antibodies, small molecules, and peptides. Their 4-step competitive colorimetric ELISA ensures precise measurement of binding between our biotinylated receptor (ligand) and immobilized human ligand (receptor).
|
|
|
|
|
|
|
|
|
Children’s immune systems do not develop ‘adaptive’ memory to protect against second time SARS-CoV-2 infection
Children have largely avoided severe COVID-19 symptoms because they have a strong initial 'innate' immune reaction that quickly defeats the virus.
|
|
Study identifies a previously unknown role of 'natural killer' immune cells
Melbourne researchers have improved our understanding of how the immune system is regulated to prevent disease, identifying a previously unknown role of 'natural killer' (NK) immune cells.
|
|
|
|
|
|
|
|
Boosting antibody-drug conjugates (ADCs) Development with Vital Reagents
Antibody-drug conjugates (ADCs) have emerged as a revolutionary therapeutic class. We facilitate ADC development with a wide range of offerings, including inspiring target protein collections, cleavable linker tools (MMPs, Cathepsin, uPA), ADC site-specific conjugation kits, and anti-payload and anti-idiotypic antibodies for immunogenicity/PK analysis.
|
|
|
|
|
|
|
|
|
Newly discovered antibody appears to block infection by all dominant variants of SARS-CoV-2 virus
A team led by researchers at Weill Cornell Medicine, the University of Wisconsin-Madison; Scripps Research and the University of Chicago has identified an antibody that appears to block infection by all dominant variants of the virus that causes COVID-19, including Omicron, the most recent.
|
|
Neuroscientists discover new way to disrupt chronic inflammation responsible for multiple sclerosis
UVA Health neuroscientists have discovered a potential way to disrupt the chronic inflammation responsible for multiple sclerosis.
|
|
|
|
|
|
|
|
Advanced Immune Checkpoint Products for Immuno-Oncology Therapy
Immune checkpoint blockade has transformed cancer therapy. ACRO empower this revolution with a comprehensive suite of immune checkpoint-related products, including high-quality proteins, inhibitor screening kits, stable/report cell lines, and PK assay kits for quantitative analysis of therapeutic antibodies.
|
|
|
|
|
|
|
|
|
Researchers reveal previously unknown properties of T cells
Certain T cells can secrete cytokines that are normally part of the innate immune system, as researchers from the Leibniz Institute for Natural Product Research and Infection Biology and an international research team discovered.
|
|
Immunomodulatory antibodies found to be successful in treating cancer when they have a looser grip
New research from the Centre for Cancer Immunology at the University of Southampton, published ahead of World Cancer Day (4 February), has shown that changing how tightly an antibody binds to a target could improve treatments for cancer.
|
|
|
|
